Rolf Grempler

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 4

Top Topics

Top Venues

Molecular cancer therapeutics

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Andreas Gollner, Dorothea Rudolph, Ulrike Weyer-Czernilofsky, Rosa Baumgartinger, Peter Jung, Harald Weinstabl, Juergen Ramharter, Rolf Grempler, Jens Quant, Joerg Rinnenthal, Alejandro Pérez Pitarch, Bojana Golubovic, Daniel Gerlach, Gerd Bader, Kristiane Wetzel, Sebastian Otto, Christian Mandl, Guido Boehmelt, Darryl B McConnell, Norbert Kraut, Patrizia Sini
Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules. Molecular cancer therapeutics (2024)
Kyle P Martin, Christine Grimaldi, Rolf Grempler, Steven Hansel, Sandeep Kumar
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics. mAbs 15 (1) (2023)
Rolf Grempler, Jennifer Ahlberg, Eva Germovsek, Priyanka Gupta, Hua Li, Minu Pilvankar, Ashish Sharma, Peter Stopfer, Steven Hansel
Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis. Advances in therapy (2023)
Rolf Grempler, Michael Wolff, Eric Simon, Ramona Schmid, Claudia Eisele, Kathrin Rieber, Elke Fischer, Sonja Mettel, Ogsen Gabrielyan, Denis Delic, Gerd Luippold, Norbert Redeman
Discovery and translation of a target engagement marker for AMP-activated protein kinase (AMPK). PloS one 13 (5) (2018)